About: Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2
Creator	Wang, Hui Niu, Peihua Tan, Wenjie Wang, Wenling Huang, Baoying Zhao, Li Liu, Jiangning Qin, Chuan Xu, Yanfeng Xu, Wenbo Zhou, Weimin Wu, Guizhen Li, Changgui Gao, Hong Lou, Zhiyong Li, Na Gao, George Zhen, Wei Bao, Linlin Yang, Xiaoming Deng, Wei Zhang, Jin Xu, Miao Wu, C Zhou, L Zhang, Yuntao Gao, G Liu, H Niu, J Wang, H Wang, W Xu, L Xu, Z Yang, W Zhang, S Zhang, Y Zhao, Y Gao, W Li, G Liang, J Xu, W Zhao, P Bao, H Deng, W Ding, Ling Fu, W Fu, Hui Huang, B Li, N Liang, Hongyang Lou, C Qin, M Quan, Y Quan, Yaru Tan, G Xu, Guangxue Yu, Shouzhi Zhang, Zhengli Zhao, Yuxiu
Source	Elsevier; Medline; PMC
abstract	Summary The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/j.cell.2020.06.008
bibo:pmid	32778225
has license	els-covid
sha1sum (hex)	f3ecff5dd787f8e4069093af1d38463d9f1f5258
schema:url	https://doi.org/10.1016/j.cell.2020.06.008
resource representing a document's title	Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2
has PubMed Central identifier	PMC7275151
has PubMed identifier	32778225
schema:publication	Cell
resource representing a document's body	covid:f3ecff5dd787f8e4069093af1d38463d9f1f5258#body_text
is schema:about of	named entity 'IL-4' named entity 'body weight' named entity 'CD3' named entity 'guinea pigs' named entity 'viral load' named entity 'guinea pigs' named entity 'animal models' named entity 'CD8 +' named entity 'immunization' named entity '28 days' named entity 'Serum' named entity 'NAb' named entity 'immunization' named entity 'Rhesus macaques' named entity 'intramuscularly' named entity 'CD4' named entity 'vaccine' named entity 'positive control' named entity 'gross anatomy' named entity 'immunizations' named entity 'intramuscularly' named entity 'rat' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software